A Phase 3 interventional study of Aria Sensor in Dysphagia and Parkinson Disease, sponsored by Northwestern University. Completed at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Northwestern University · Phase 3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 230 studies in Deglutition Disorders with a site in United States — 43 open to participants now, 48 under way, none of them phase 3. Deglutition Disorders · United States.
Among the 230 studies in Deglutition Disorders with a site in United States, this one is the 70th largest by enrollment of the 165 interventional ones that give a count, is one of 9 that started in 2025, is one of 6 in phase 3, and was the 156th registered.
875 studies on the registry are indexed under Deglutition Disorders; 237 are open to participants now.
Browse Deglutition Disorders studies →43 of the 230 studies in Deglutition Disorders with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States, Mali
Ages 18–65
Medical University of South Carolina · Sites in United States
Ages up to 6 mo
Johns Hopkins University · Sites in United States
Ages 5–21
Nova Southeastern University · Sites in United States
Ages 18–99
Vanessa Torrecillas · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 137 Deglutition Disorders studies recruiting now, 75 (55%) set no upper age limit and 26 (19%) stop at 75 or younger; 15 take children under 18; 20 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
230 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 29 · Phase 3 12 · Phase 4 5
First in 1979; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 59 is close to the median of 60 across 581 interventional studies indexed under Deglutition Disorders.
Median enrollment 50 across the 165 interventional studies, 62 across the 64 observational. Of the 156 that completed or were terminated, 54 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 230 have an industry lead sponsor. The 10 most frequent:
Northwestern University is the lead sponsor of 1,424 studies on the registry; 199 are open to participants now.
Of its 105 completed or terminated interventional studies of FDA-regulated products, 78 (74%) have results posted.
Northwestern University has 4 studies filed under Deglutition Disorders — fewer than ten, so there is no comparison to draw.
21 of the studies in Deglutition Disorders with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05497219University Health Network, TorontoReference Values for Videofluoroscopic Measures of Swallowing | 2026-11-30 |
| NCT06670521University of Colorado, DenverCorticosteroids for Post-Extubation Dysphagia | 2026-11-30 |
| NCT05603897University of MiamiNon-standardized vs. Standardized Screening for Dysphagia | 2026-11-30 |
| NCT02838316Peter Belafsky, MDAutologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia | 2026-12 |
| NCT04074356Vanderbilt University Medical CenterNon-invasive Markers of Esophageal Function in Adults | 2026-12-30 |
Add all 21 to your calendar (.ics) → With an account.
Among the 230 studies in Deglutition Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is the development and early-stage validation of a wearable sensor for dysphagia in patients with PD.
The project goal is the development and early stage validation of a wearable sensor for dysphagia in patients with PD. The first phase of the program involves engineering goals relating to increasing the battery life of this sensor to 48 hours between charges and reducing the overall form factor size. The second phase of the program is to conduct focus groups with PD patients to assess sensor usability, set up burden, and design feedback. The third phase of the study will assess the feasibility of the sensor to detect and cue swallowing in a small cohort of PD patients.
Inclusion criteria. Age ≥22. English speaking. Diagnosis of idiopathic Parkinson's disease of any Hoehn and Yahr stage (I-V), determined by a neurologist.
Mild to moderate sialorrhea defined as a score of ≥ 11* on the Radboud Oral Motor Inventory for Parkinson's Disease (ROMP)-Saliva (C) subscale Subjects must be in the "on" phase of their medication during all study assessments. The "on" phase is defined as the period when the participant's medication is at peak effectiveness, minimizing motor fluctuations and enabling optimal motor function.
Study Exclusion Criteria. History of aspiration pneumonia within the past 12 months. Unable to swallow saliva without a maneuver. Actively receiving treatment for swallowing disorders or sialorrhea. Current alcohol/drug abuse. Diagnosed with neurological disorders other than PD. End stage dementia. History of head and neck cancer or surgery. Unable to demonstrate competency with the user-friendly sensor platform technology.
Known allergy to contrast material used during MBSS. Known allergy to sensor adhesive. Indwelling tracheostomy tube. Nasogastric (NG) feeding tube. Currently pregnant.
The Aria sensor is a wearable patch that continuously monitors physiological signals and provides vibratory haptic cues to increase swallow frequency. The intervention consists of using the sensor over a 3-week period, with active haptic cueing during Week 2 only.
Device: Aria Sensor
The Aria sensor is a wearable patch that continuously monitors physiological signals and provides vibratory haptic cues to increase swallow frequency. The intervention consists of using the sensor over a 3-week period, with active haptic cueing during Week 2 only.
Percent agreement with Gold Standard
Percent agreement between experimental sensor Gold standard (GS) respiratory inductance plethysmography (RIP) with Inductotrace System®, Ambulatory Monitoring)
Time frame: 1 year
Change in mean swallow frequency during haptic cueing week
This outcome measures the change in the average number of swallows per hour during the intervention week (Week 2, with haptic cueing) compared to baseline (Week 1, no cueing). Swallows will be manually labeled from sensor audio recordings by at least three independent annotators.
Time frame: Week 1 to Week 2
Change in algorithm-detected swallow frequency during haptic cueing week
This outcome measures the change in the mean swallow frequency as automatically detected by the Aria sensor's AI algorithm, comparing Week 2 (intervention) to Week 1 (baseline). Performance will be benchmarked against manually annotated swallows.
Time frame: Week 1 to Week 2
Change in Sialorrhea Clinical Scale for Parkinson's Disease (SCS-PD) score
Assesses the effect of the intervention on drooling symptoms using the Sialorrhea Clinical Scale for PD. Participants complete this validated questionnaire at baseline, during, and after the intervention.
Time frame: Baseline to Week 3
Change in ROMP-Swallowing Subscale score
Assesses changes in self-reported swallowing function using the Swallowing Subscale of the Radboud Oral Motor Inventory for Parkinson's Disease (ROMP). The ROMP is a validated, PD-specific measure.
Time frame: Baseline to Week 3
Change in participant adherence to haptic cueing
Evaluates adherence to the intervention by quantifying the percentage of haptic cues that are followed by a swallow within 5 seconds during Week 2. Cue-swallow pairings are based on algorithmic and manual labeling.
Time frame: Week 2
Change in Modified Barium Swallow Impairment Profile (MBSImP)
Subsample of participants will undergo video fluoroscopy to evaluate swallowing function. The MBSImP scores will assess changes in swallow physiology pre- and post-intervention.
Time frame: Baseline to Week 3
Change in Penetration-Aspiration Scale Score
Assesses airway protection during swallowing via penetration-aspiration scale scores from videofluoroscopic studies in a subsample of participants.
Time frame: Baseline to Week 3
Ran from Apr 2025 to primary completion in Oct 2026, 18 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.